Key result
Single access TAVI linked to ~56% fewer 30-day safety events vs dual access.
Why the study?
Single-access TAVI may reduce access-site complications compared to dual-access, but this approach has not been widely studied.
Does single-access TAVI improve device success and 30-day safety compared to dual-access TAVI in patients undergoing transfemoral TAVI with a balloon-expandable valve?
Cohort (n=532)
Does single-access TAVI improve device success and 30-day safety compared to dual-access TAVI in patients undergoing transfemoral TAVI with a balloon-expandable valve?
Answers are grounded in this paper and cite their sources.
Single-access TAVI using a balloon-expandable valve is a feasible and safe strategy that reduces procedure time, contrast use, and radiation exposure while improving the 30-day safety profile compared to dual-access TAVI.
BACKGROUND: Vascular complications are more frequently encountered in patients undergoing transcatheter aortic valve implantation (TAVI) compared to surgical aortic valve replacement. Single access (SA) TAVI may reduce access-site complications, but this approach has not been widely studied. OBJECTIVES: The aim of the study was to compare clinical outcomes of SA vs dual access (DA) TAVI using balloon-expandable valve Sapien 3 Ultra. METHODS: This was a retrospective analysis of consecutive patients who underwent TAVI using balloon-expandable valve. Data were prospectively entered into a dedicated web-based database. The co-primary endpoints were device success and 30-day safety endpoints, defined according to the Valve Academic Research Consortium 3. A propensity score matching with a 1:1 ratio was performed comparing SA vs DA TAVI. RESULTS: Of 532 patients who had transfemoral TAVI, 117 (22%) underwent the SA approach. Propensity score matching analysis yielded a well-balanced 204 patients (102 in each group). SA was associated with a significant reduction in contrast use, fluoroscopy time, radiation exposure, and total procedure time. Device success was comparable between the 2 groups (3.9% vs 3.9%; OR: 1.00; 95% CI: 0.24-4.11; P > 0.99). The 30-day safety profile of the Valve Academic Research Consortium 3 was significantly better in patients who underwent SA vs DA TAVI (15.0% vs 28.9%; OR: 0.44; 95% CI: 0.22-0.88; P = 0.02). This was derived from a lower incidence of severe paravalvular regurgitation and new pacemaker implantation. CONCLUSIONS: SA is a feasible and safe strategy compared to DA TAVI. It was associated with quicker procedure times, lower contrast and radiation exposure, and a better 30-day safety profile than the DA strategy. Future randomized studies are needed to further assess this strategy.
No takes yet. Share an insight, caveat, or question.
Omari et al. (2025) conducted a cohort in Transcatheter aortic valve implantation (TAVI) (n=532). Single access (SA) TAVI vs. Dual access (DA) TAVI was evaluated on 30-day safety endpoints (Valve Academic Research Consortium 3) (OR 0.44, 95% CI 0.22-0.88, p=0.02). Single access TAVI was associated with a significantly better 30-day safety profile compared to dual access TAVI (15.0% vs 28.9%; OR 0.44; 95% CI 0.22-0.88; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: